Introduction. The term metabolic dysfunction-associated steatotic liver disease (MASLD) marks a paradigm shift from the traditional concept of non-alcoholic fatty liver disease (NAFLD), redefining hepatic steatosis as a systemic metabolic disorder with positive diagnostic criteria. MASLD is closely intertwined with obesity, insulin resistance, type 2 diabetes mellitus, dyslipidemia, arterial hypertension, chronic kidney disease, and cardiovascular disease. Cardiovascular events are the leading cause of death in this population, exceeding liver-related mortality. Pathophysiologically, dysfunctional adiposity, chronic inflammation, oxidative stress, gut dysbiosis, and ectopic lipid deposition promote hepatic steatosis and fibrosis while also driving atherosclerosis, heart failure with preserved ejection fraction, atrial fibrillation, and renal injury. Fibrosis severity is the strongest predictor of adverse hepatic and extrahepatic outcomes. Emerging frameworks such as the cardio- vascular-kidney-metabolic (CKM) and the cardiovascular-renal-hepatic-metabolic (CRHM) syndromes formally integrate MASLD into multisystem disease staging. Non-invasive tools, including FIB-4 and elastography, enable early risk stratification, while novel therapies, such as GLP-1 receptor agonists, dual incretin agonists, and SGLT2 inhibitors, offer multiorgan protection.This review highlights MASLD as the hidden nexus of the cardio-renal-metabolic continuum and underscores the need for holistic, multidisciplinary management.
Keywords: MASLD, cardio-renal-metabolic syndrome, fibrosis, HFpEF, GLP-1 receptor agonists.
Address for correspondence:
Ergita NELAJ
Department of Internal Medicine, University Hospital Center “Mother Teresa”, Tirana, Albania
Address: Dibra’s Street no 370, Tirana, Albania
Email: dr_ergi@yahoo.com;
